Source: International Congress 2019 – Clinical studies of asthma treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Chapman (Toronto, Canada), H. Watz (Grosshansdorf, Germany), J. Beier (Wiesbaden, Germany), D. Singh (Manchester, United Kingdom), J. Hohlfeld (Hannover, Germany), Z. Diamant (Lund, Sweden), V. Scholz (Berlin, Germany), A. Sarkar (Oberhaching, Germany), I. Jones (Basel, Switzerland), R. Li (Beijing, China), P. Pinot (Basel, Switzerland), H. Tillmann (Basel, Switzerland). Lung function normalization with indacaterol/glycopyrronium/mometasone furoate in patients with asthma. 2539

Member's Comments

No comment yet.

Related content which might interest you: Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low-mid dose assessment Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008 Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Mid-high dose assessment Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003 Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001 Improvement of the length tension relation in severe COPD with vilanterol trifenatate/fluticasone furoate Source: International Congress 2017 – Management of COPD Year: 2017 Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003 Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2-agonist, vilanterol (VI) combination in reducing COPD exacerbations Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Comparative effects of Mometason furoate and Zafirlukast in treatment of nasal polyps in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002 Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007 Inhaled vilanterol trifenatate/fluticasone furoate (VFF) improves respiratory muscle function and walking performance in severe COPD without change in pulmonary function Source: International Congress 2017 – Management of COPD Year: 2017 Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 379s Year: 2004 Additive effect of Zafirlukast in combination with Mometason furoate in treatment of Nasal polyps in patients with mild persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003 Lung function and symptom improvements with fluticasone propionate/salmeterol 250/50 and ipratropium/albuterol in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 Response to fluticasone propionate in controlling airway inflammation in steroid-naïve asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 317s Year: 2006